{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-381076","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2026-09-03T12:05:06+00:00","discovered_at":"2026-09-03T12:10:00.551516+00:00","generated_at":"2026-09-03T12:10:07.352202+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LB Pharmaceuticals appoints Joseph Miller as CFO, effective September 2, 2026","bullets":["Joseph M. Miller named CFO; previously CFO of Aurinia Pharmaceuticals (April 2020–March 2026).","Initial annual base salary of $530,000; target bonus of 40% of base salary.","Inducement option for 200,000 shares vesting over 4 years, 25% on first anniversary.","Company nears NOVA-2 clinical trial readout and prepares for potential LB-102 launch in schizophrenia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-381076","json":"https://secwatch.observer/filing/0001193125-26-381076.json","markdown":"https://secwatch.observer/filing/0001193125-26-381076.md","text":"https://secwatch.observer/filing/0001193125-26-381076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526381076/0001193125-26-381076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526381076/d26110d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-03T12:10:07.352202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0dcb22e508","claim":"Joseph M. Miller was appointed as Chief Financial Officer at LB PHARMACEUTICALS INC.","evidence_excerpt":"On September 3, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Joseph M. Miller has been appointed to serve as the Company’s Chief Financial Officer, effective as of September 2, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526381076/0001193125-26-381076-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}